902765-53-1

Upstream product

• 502649-09-4 2-chloro-6-ethyl-4-piperazin-1-ylthieno[2,3-d]pyrimidine 
• 14002-51-8 4-biphenyl-carboxylic acid chloride 
• 502644-41-9 tert-butyl 4-(2-chloro-6-ethylthieno[2,3-d]pyrimidin-4-yl)-piperazine-1-carboxylate 
• 87478-74-8 2,4-dichloro-6-ethyl-thieno-[2,3-d]-pyrimidine 
• 502649-08-3 6-ethylthieno[2,3-d]pyrimidine-2,4-diol 
• 19156-63-9 2-amino-5-ethylthiophene-3-carboxylic acid methyl ester 

Downstream Products

• 1196669-82-5 C₃₁H₃₃N₇O₃S 
• 1196669-71-2 C₃₀H₃₄N₆OS 
• 1196669-77-8 C₃₁H₃₄N₆O₂S 
• 1196669-79-0 C₂₈H₂₉N₅O₂S 
• 1196669-74-5 C₂₇H₂₉N₅O₂S 
• 1196669-73-4 C₃₁H₃₁F₃N₆O₂S 
• 1196669-80-3 C₂₈H₃₁N₅O₂S 
• 911214-76-1 4-[4-(1,1'-biphenyl-4-ylcarbonyl)piperazin-1-yl]-6-ethylthieno[2,3-d]pyrimidin-2-amine 

Relevant academic research and scientific papers

Thienopyrimidine-based P2Y12 platelet aggregation inhibitors

Herein we describe the design and synthesis of a novel series of potent thienopyrimidine P2Y12 inhibitors and the negative impact protein binding has on the inhibition of platelet aggregation.

THIENO[2,3-d]PYRIMIDINE COMPOUNDS

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) wherein A1, A2, A3, A4, A5, A6, A7, A

4-PIPERAZINYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) wherein A1 , A2, A3, A4, A5, A6, A7, Asup

4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: (I) wherein A1, A2, A3, A4, A5, A6, A7, As

4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), wherein A1, A2, A3, A4, A5, A6, A7, A8, X4, X6, R2, R4, R5, and R6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

THIENO [2,3-D] PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I): wherein A1, A2, A3, A4, A5, A6, A7, A8, X4, X6, R2, R4, R5, and R6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.